Clinical Trial Update: PQ203 in Advanced Malignant Tumors Including Triple Negative Breast Cancer [Phase 1]

View source ↗

Summary

PQ203 from ProteinQure Inc. is in a Phase 1 trial for advanced malignant tumors, including triple-negative breast cancer, and recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• PQ203

Snippet

Sponsor: ProteinQure Inc. | Conditions: Triple Negative Breast Cancer (TNBC), Advanced Solid Tumors Cancer | Phase 1 | Status: RECRUITING